I think people are forgetting the possible income stream coming...

I think people are forgetting the possible income stream coming from 1102 under compassionate usage. Tysabri ranges from 40k upwards of 60k per year whereas 1102 will be around 30k. Every 33 patients who take up 1102 equates to approx. $1million. 200 patients = $6 million.
That alone is exciting enough and I am looking forward to some upcoming ann on this progressing. Throw in a licensing deal from one of the several parties currently doing due dilligence on 1103 and it is easy to see how ridiculously undervalued imo Anp currently is. Quite simply there is no comparison anywhere in Aust biotech with a mc of 15 mill and the potential to finally reward its shareholders in the short term.
I don't like targets but have long thought a 60mill mc (approx36c)more than just achievable with what is about to unfold imo.
Re upfront... 15mill would not be an unreasonable expectation....said that the other day it would probably be larger than out current mc.